Moist Exposed Burn Ointment Effectiveness for Capecitabine Associated Grade II and III Hand Foot Syndrome on Stage III Colonic

Authors

  • Budhi Ida Bagus Department of Surgery, Sebelas Maret University, Surakarta, Indonesia https://orcid.org/0000-0002-0310-7415
  • Nunik Agustriani Department of Pediatric Surgery, Sebelas Maret University, Surakarta, Indonesia
  • Rieva Ermawan Department of Orthopaedic and Traumatology Surgery, Sebelas Maret University, Surakarta, Indonesia
  • Suwardi Suwardi Department of Pediatric Surgery, Moewardi General Hospital, Surakarta, Indonesia
  • Amru Sungkar Department of Plastic Surgery, Moewardi General Hospital, Surakarta, Indonesia
  • Ikhdin R. Saadhi Department of Surgery, Moewardi General Hospital, Surakarta, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2021.6959

Keywords:

Moist exposed burn ointment, Hand foot syndrome, Colonic adeno carcinoma

Abstract

Background:Hand-foot syndrome (HFS), also known as palmoplantar erythrodysesthesia, is a common adverse effect of the fluoropyrimidine chemotherapy agent capecitabine. Hand-foot syndrome of any grade is reported to affect 43% to 71% of patients treated with single-agent capecitabine chemotherapy. Although not life-threatening, it can have adverse effects on the quality of life (QoL) and daily living activities of a patient.  Sometimes the dose interruptions and reductions required after observation of HFS can also impact on dose intensity and treatment outcomes.  As an option for the treatment of this case, we would reported our preliminary study of the effectiveness of moist exposed burn ointment (MEBO) for stage II and III HFS.

 

Methods:  We will evaluate the clinical sign and symptoms of hand foot syndrome grade II and III associated with capecitabine as adjuvant chemotherapy agent on advanced stage colorectal cancer.  All patients with HFS will treated with topical MEBO twice daily, the clinical improvement of the symptoms will be recorded.

 

Results: We reported 8 cases of grade II and III hand foot syndrome, 2 patients were grade III HFS and the others were grade II.  These symptoms occurred after 2 until 3 months after capecitabine administration for locally advanced (stage III) colonic adenocarsinoma.  Topical MEBO were used twice a day for 3 months, pain reduction was achieved with no capicetabine dose interruption and reduction during chemotherapy period.  Allergic reaction was not found during and after MEBO application in this case.

 

Conclusion:Moist exposed burn ointment was an effective treatment option in managing hand foot syndrome, better option in reducing the pain without interrupting the capecitabine doses.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352(26):2696-704. https://doi.org/10.1056/nejmoa043116 PMid:15987918 DOI: https://doi.org/10.1056/NEJMoa043116

Ota M, Tatsumi K, Suwa H, Watanabe J, Watanabe K, Osada S, et al. The effect of pyridoxine for prevention of hand-foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine: A randomized study. Hepatogastroenterology. 2014;61(132):1008-13. PMid:26158157

Yap YS, Kwok LL, Syn N, Chay WY, Chia JW, Tham CK, et al. Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: A randomized clinical trial. JAMA Oncol. 2017;3(11): 1538-45. https://doi.org/10.1001/jamaoncol.2017.1269 PMid:28715540 DOI: https://doi.org/10.1001/jamaoncol.2017.1269

Zheng A, Ma H, Liu X, Huang Q, Li Z, Wang L, Zeng N, Wu B. Effects of moist exposed burn therapy and ointment (MEBT/ MEBO) on the autophagy mTOR signalling pathway in diabetic ulcer wounds. Pharm Biol. 2020;58(1):124-30. https://doi.org/10.1080/13880209.2019.1711430 PMid:31967912 DOI: https://doi.org/10.1080/13880209.2019.1711430

Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, et al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: Results of a randomized, double-blind, placebo-controlled study. J Clin Oncol. 2010;28(24):3824-9. https://doi.org/10.1200/jco.2010.29.1807 PMid:20625131 DOI: https://doi.org/10.1200/JCO.2010.29.1807

Azuma Y, Hata K, Sai K, Udagawa R, Hirakawa A, Tohkin M, et al. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer. Biol Pharm Bull. 2012;35(5):717-24. https://doi.org/10.1248/bpb.35.717 PMid:22687407 DOI: https://doi.org/10.1248/bpb.35.717

Lou Y, Wang Q, Zheng J, Hu H, Liu L, Hong D, et al. Possible pathways of capecitabine-induced hand-foot syndrome. Chem Res Toxicol. 2016;29(10):1591-601. https://doi.org/10.1021/acs.chemrestox.6b00215 PMid:27631426 DOI: https://doi.org/10.1021/acs.chemrestox.6b00215

Son HS, Lee WY, Lee WS, Yun SH, Chun HK. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. Yonsei Med J. 2009;50(6):796-802. https://doi.org/10.3349/ymj.2009.50.6.796 PMid:20046420 DOI: https://doi.org/10.3349/ymj.2009.50.6.796

Nagore E, Insa A, Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (“hand-foot”) syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1(4):225-34. https://doi.org/10.2165/00128071-200001040-00004 PMid:11702367 DOI: https://doi.org/10.2165/00128071-200001040-00004

Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intra venous 5-fluorouracil/leucovorin. Ann Oncol. 2002;13(4):566-75. https://doi.org/10.1093/annonc/mdf089 PMid:12056707 DOI: https://doi.org/10.1093/annonc/mdf089

Downloads

Published

2021-09-06

How to Cite

1.
Ida Bagus B, Agustriani N, Ermawan R, Suwardi S, Sungkar A, Saadhi IR. Moist Exposed Burn Ointment Effectiveness for Capecitabine Associated Grade II and III Hand Foot Syndrome on Stage III Colonic. Open Access Maced J Med Sci [Internet]. 2021 Sep. 6 [cited 2024 Mar. 29];9(B):971-4. Available from: https://oamjms.eu/index.php/mjms/article/view/6959

Most read articles by the same author(s)